Related Experiment Videos
Fosphenytoin use in children
1Division of Child Neurology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298, USA.
Insights
Fosphenytoin offers a safer and more flexible alternative to phenytoin for seizure management in children. This prodrug can be administered intramuscularly and intravenously, overcoming limitations of traditional phenytoin therapy.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Phenytoin is a common treatment for acute seizures in children, but its administration has limitations.
- Intramuscular (i.m.) administration of phenytoin is not possible.
- Intravenous (i.v.) phenytoin administration can be challenging in newborns and critically ill infants due to venous access issues.
Purpose of the Study:
- To evaluate the safety and efficacy of fosphenytoin, a phenytoin prodrug, in pediatric populations.
- To compare fosphenytoin administration routes (i.v. and i.m.) with phenytoin.
- To investigate the pharmacokinetic profile of fosphenytoin in children and young adults.
Main Methods:
- Clinical studies involving i.v. and i.m. fosphenytoin administration.
- Assessment of efficacy, safety, and pharmacokinetics.
- Comparison between pediatric patients (5-18 years) and young adults.
Main Results:
- Fosphenytoin can be safely administered via the i.m. route.
- Fosphenytoin offers advantages for i.v. administration compared to phenytoin.
- Efficacy, safety, and pharmacokinetics of fosphenytoin were found to be similar in children (5-18 years) and young adults.
Conclusions:
- Fosphenytoin presents a viable alternative to phenytoin for pediatric seizure treatment, offering improved administration options.
- Further research is ongoing to determine the safety and pharmacokinetic profile of fosphenytoin in younger children and infants.
Abstract:
Phenytoin is widely used for the prevention and treatment of acute seizures in children. Although it has the advantage of being available in parenteral form, it cannot be given through the i.m. route. Furthermore, problems with venous accessibility and maintenance may complicate i.v. administration of phenytoin in newborns and very sick infants. Fosphenytoin, a new phenytoin prodrug, can be safely administered through the i.m. route, and, because of the physical characteristics of its formulation, it offers advantages over phenytoin for i.v. administration. Clinical studies with i.v. and i.m. fosphenytoin demonstrate that the efficacy, safety, and pharmacokinetics of this drug are similar in 5- to 18-year-old children and in young adults. The safety and pharmacokinetic profile of i.v. and i.m. fosphenytoin in younger children and infants is currently being investigated.